<DOC>
	<DOC>NCT00238719</DOC>
	<brief_summary>To determine the anxiolytic efficacy, safety, and tolerability of a flexible-dose of venlafaxine extended release (ER) administered for 16 weeks in the treatment of children and adolescent outpatients with social anxiety disorder (generalized) in a placebo-controlled study.</brief_summary>
	<brief_title>Study Evaluating Venlafaxine ER in Children and Adolescents With Social Anxiety Disorder</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Anxiety Disorders</mesh_term>
	<mesh_term>Phobic Disorders</mesh_term>
	<mesh_term>Venlafaxine Hydrochloride</mesh_term>
	<criteria>Male or female outpatient 817 year old diagnosis of Social Anxiety Disorder concomitant psychiatric or medical disorders which interfere with safety or assessment</criteria>
	<gender>All</gender>
	<minimum_age>8 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>May 2006</verification_date>
	<keyword>Social Anxiety</keyword>
	<keyword>Children Disorders</keyword>
</DOC>